Outcome at 5 years | Relative MEF2C expression | P value* | |||
---|---|---|---|---|---|
Low (Q1–3) | High (Q4) | Hazard ratioa | 95 % confidence interval | ||
All patients | n = 563 | n = 188 | |||
OS | 67 ± 4 % | 55 ± 8 % | 1.385 | 1.07–1.80 | 0.014 |
EFS | 54 ± 4 % | 38 ± 7 % | 1.510 | 1.21–1.88 | <0.001 |
RR | 35 ± 5 % | 53 ± 9 % | 1.813 | 1.36–2.42 | <0.001 |
Low-risk patients | n = 255 | n = 29 | |||
OS | 81 ± 5 % | 76 ± 20 % | 1.433 | 0.43–4.82 | 0.561 |
EFS | 69 ± 6 % | 51 ± 20 % | 1.597 | 0.90–2.82 | 0.104 |
RR | 23 ± 6 % | 49 ± 20 % | 2.290 | 1.26–4.17 | 0.011 |
Standard-risk patients | n = 230 | n = 123 | |||
OS | 55 ± 7 % | 55 ± 9 % | 0.992 | 0.71–1.38 | 0.961 |
EFS | 42 ± 7 % | 38 ± 9 % | 1.143 | 0.86–1.52 | 0.356 |
RR | 49 ± 8 % | 55 ± 11 % | 1.270 | 0.88–1.83 | 0.201 |
High-risk patients | n = 69 | n = 30 | |||
OS | 52 ± 12 % | 37 ± 10 % | 1.452 | 0.81–2.59 | 0.204 |
EFS | 31 ± 11 % | 29 ± 17 % | 1.155 | 0.70–1.92 | 0.576 |
RR | 46 ± 16 % | 47 ± 27 % | 1.381 | 0.59–3.22 | 0.446 |